| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 596.1MM | +11% |
| Operating Income | 612.9MM | - |
| Operating Expenses | -16.8MM | - |
| Net Income | 494.3MM | - |
| R&D | 500K | -99% |
| G&A | 59.2MM | +3% |
| Amortization | 0 | - |
| Interest Expense | 47.3MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industr
Royalty Pharma's (NASDAQ:RPRX) stock up by 8.1% over the past three months. Given that stock prices are usually aligned...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical
It's been a good week for Royalty Pharma plc ( NASDAQ:RPRX ) shareholders, because the company has just released its...
Royalty Pharma ( NASDAQ:RPRX ) Full Year 2023 Results Key Financial Results Revenue: US$2.35b (up 5.2% from FY 2022...
Decoding the Financials and Future Prospects in Royalty Pharma's Latest 10-K Filing
Q4 and Full Year 2023 Financial Performance Overview
Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023Announced transactions of up to $4.0 billion in 2023Full year 2024 guidance: Portfolio Receipts of $2,600 to $2,700 million (reflecting royalty receipts growth of 5% to 9% year/year) excluding future transactions NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results f
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference
The board of Royalty Pharma plc ( NASDAQ:RPRX ) has announced that the dividend on 15th of March will be increased to...